12.52
-0.20 (-1.57%)
| Previous Close | 12.72 |
| Open | 12.74 |
| Volume | 101,916 |
| Avg. Volume (3M) | 287,222 |
| Market Cap | 418,473,504 |
| Price / Book | 1.19 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 |
| Diluted EPS (TTM) | -5.82 |
| Total Debt/Equity (MRQ) | 0.07% |
| Current Ratio (MRQ) | 24.19 |
| Operating Cash Flow (TTM) | -54.68 M |
| Levered Free Cash Flow (TTM) | -33.27 M |
| Return on Assets (TTM) | -24.17% |
| Return on Equity (TTM) | -36.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | MBX Biosciences, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 3.24% |
| % Held by Institutions | 98.62% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 44.00 (Guggenheim, 251.44%) | Buy |
| Median | 41.00 (227.48%) | |
| Low | 38.00 (JMP Securities, 203.51%) | Buy |
| Average | 41.00 (227.48%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 10 Apr 2025 | 44.00 (251.44%) | Buy | 6.27 |
| JMP Securities | 10 Apr 2025 | 38.00 (203.51%) | Buy | 6.27 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 May 2025 | Announcement | MBX Biosciences to Participate in June Investor Conferences |
| 12 May 2025 | Announcement | MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
| 22 Apr 2025 | Announcement | MBX Biosciences to Participate in Citizens and RBC May Investor Conferences |
| 07 Apr 2025 | Announcement | MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors |
| 26 Mar 2025 | Announcement | MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference |
| 17 Mar 2025 | Announcement | MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights |
| 05 Mar 2025 | Announcement | MBX Biosciences Announces Additions to Leadership Team |
| 03 Mar 2025 | Announcement | MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |